Dr. John Lechleiter, President and Chief Operating Officer of Eli Lilly, to Visit Phillips Plastics Corporation Medical Device Campus
Menomonie, WI - Dr. John Lechleiter, President and Chief Operating Officer of Eli Lilly will visit Phillips Plastics Corporation on Tuesday, April 3, 2007 to recognize Phillips Plastics efforts in helping create and launch the Luxura HD insulin delivery device. Phillips involvement included the design and development of the critical components for the Luxura HD device, for which time- to-market was expedited because of the company's experience on previous Lilly programs.
Phillips Plastics has partnered with Lilly for over ten years to develop and manufacture ground-breaking devices that have advanced diabetes treatment and care. According to Phillips' Medical Device Plant Manager, Dave Thoreson, "The people at Phillips are excited to be manufacturing this device which will help improve the lives of diabetic patients. In addition, we are equally excited this reusable insulin delivery device is being launched in the United States."
According to the American Diabetes Association, 21 million children and adults have diabetes and it is the sixth leading cause of death in the United States. "We are honored to be recognized by Lilly for our efforts in helping launch this device as we believe in the importance of providing quality diabetic care for all people suffering from this disease. The development of the Luxura HD not only reinforces Lilly's commitment to diabetes but also pediatric medicine, for patients who will benefit from using this device include Type 1 infants and Type 1 children under the age of 10," adds Thoreson.
Lilly, a leading multi-billion dollar innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Lilly introduced the world's first commercially available insulin product for treating diabetes, then a fatal disease, in 1923. In the most significant breakthrough in diabetes care since then, Lilly introduced the world's first human insulin in 1982.
A product release on the Luxura HD pen can be found at: http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=230738
Additional information about Lilly is available at: http://www.lilly.com
For more information, contact: